Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
1682
mi
from 98109
Dallas, TX
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
1682
mi
from 98109
Dallas, TX
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
UCLA Jonsson Comprehensive Cancer Center
979
mi
from 98109
Los Angeles, CA
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
UCLA Jonsson Comprehensive Cancer Center
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
Kansas City Veterans Affairs Medical Center
1503
mi
from 98109
Kansas City, MO
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
Kansas City Veterans Affairs Medical Center
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
2329
mi
from 98109
Chapel Hill, NC
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania:Abramson Cancer Center
2371
mi
from 98109
Philadelphia, PA
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania:Abramson Cancer Center
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
Saint Michael's Hospital
2066
mi
from 98109
Toronto,
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
Saint Michael's Hospital
2066
mi
from 98109
Toronto,
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
1890
mi
from 98109
Houston, TX
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
1029
mi
from 98109
Aurora, CO
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Georgetown University
2322
mi
from 98109
Washington,
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Georgetown University
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
University of Maryland
2327
mi
from 98109
Baltimore, MD
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
University of Maryland
2327
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medical Center
2329
mi
from 98109
Baltimore, MD
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medical Center
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Mt. Sinai Medical Center
2402
mi
from 98109
New York, NY
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Mt. Sinai Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Columbia University
2400
mi
from 98109
New York, NY
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Columbia University
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
1678
mi
from 98109
Peoria, IL
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
1678
mi
from 98109
Peoria, IL
Click here to add this to my saved trials
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
2352
mi
from 98109
Richmond, VA
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1119
2082
mi
from 98109
Birmingham, AL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1119
2082
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1133
2240
mi
from 98109
Dothan, AL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1133
2240
mi
from 98109
Dothan, AL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1107
2714
mi
from 98109
Hollywood, FL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1107
2714
mi
from 98109
Hollywood, FL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1123
2643
mi
from 98109
Naples, FL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1123
2643
mi
from 98109
Naples, FL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1106
2536
mi
from 98109
Port Orange, FL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1106
2536
mi
from 98109
Port Orange, FL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1137
2586
mi
from 98109
Sweetwater, FL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1137
2586
mi
from 98109
Sweetwater, FL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1131
1733
mi
from 98109
Chicago, IL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1131
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1127
1761
mi
from 98109
Urbana, IL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1127
1761
mi
from 98109
Urbana, IL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1113
2317
mi
from 98109
Chevy Chase, MD
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1113
2317
mi
from 98109
Chevy Chase, MD
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1111
1757
mi
from 98109
Troy, MI
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1111
1757
mi
from 98109
Troy, MI
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1109
2411
mi
from 98109
Great Neck, NY
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1109
2411
mi
from 98109
Great Neck, NY
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1114
2161
mi
from 98109
Rochester, NY
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1114
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1118
2362
mi
from 98109
Raleigh, NC
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1118
2362
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1112
1967
mi
from 98109
Cincinnati, OH
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1112
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1105
1952
mi
from 98109
Germantown, TN
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1105
1952
mi
from 98109
Germantown, TN
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1102
1977
mi
from 98109
Hermitage, TN
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1102
1977
mi
from 98109
Hermitage, TN
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1136
1687
mi
from 98109
DeSoto, TX
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1136
1687
mi
from 98109
DeSoto, TX
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1121
1890
mi
from 98109
Houston, TX
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1121
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1116
1743
mi
from 98109
Temple, TX
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1116
1743
mi
from 98109
Temple, TX
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1103
675
mi
from 98109
Ogden, UT
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1103
675
mi
from 98109
Ogden, UT
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1130
2350
mi
from 98109
Richmond, VA
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1130
2350
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1128
2248
mi
from 98109
Roanoke, VA
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1128
2248
mi
from 98109
Roanoke, VA
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1115
1
mi
from 98109
Seattle, WA
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1115
1
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1101
1
mi
from 98109
Seattle, WA
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1101
1
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1108
1681
mi
from 98109
Wauwatosa, WI
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1108
1681
mi
from 98109
Wauwatosa, WI
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1143
941
mi
from 98109
Thousand Oaks, CA
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1143
941
mi
from 98109
Thousand Oaks, CA
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1138
2724
mi
from 98109
Miami, FL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1138
2724
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Arena 1141
2547
mi
from 98109
Orlando, FL
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Arena 1141
2547
mi
from 98109
Orlando, FL
Click here to add this to my saved trials